Double Blind, two dose, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients
Experimental medication to improve cognition in schizophrenia patients
Sponsor: NIH - NIMH
Enrolling: Male and Female Patients
IRB Number: 7370
U.S. Govt. ID: NCT02978599
Contact: James Gangwisch PhD: 646-774-8433 /
Additional Study Information: AVL-3288 is an experimental medication that effects the nicotine receptors in the brain that isbeing initially developed for the treatment of cognitive problems in patients with schizophreniaaccompanied. To date, no specific treatments for cognitive deficits in schizophrenia exist and approvedtherapies do not satisfactorily improve cognition.
This study is closed
Jeffrey Lieberman, MD
Do You Qualify?
Do you suffer from schizophrenia? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
James Gangwisch PhD